About ISIS 369645
ISIS 369645 is an antisense drug that acts as an inhibitor of the IL-4/IL-13 cytokine signaling pathways, which play an important role in asthma. In preclinical studies, inhibition of IL-4/IL-13 signaling pathways reduced lung cytokine production, inflammation, and airway hyper-responsiveness and when delivered by inhalation can rapidly distribute to target tissues at therapeutic doses.
About Thomas, McNerney & Partners
Thomas, McNerney & Partners, LLC, is a health care private equity firm that invests in life science and medical technology companies. Employing a multi-stage investment approach, Thomas, McNerney & Partners has just under $600 million in assets under management and provides seed and early stage funding to help entrepreneurs launch companies, as well as growth capital to emerging companies for furthering clinical development or for expansion of product commercialization. For more information, please visit http://www.tm-partners.com .
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel
drugs for its product pipeline and for its partners. The Company has
successfully commercialized the world's first antisense drug and has 17
drugs in development. Isis' drug development programs are focused on
treating cardiovascular and metabolic diseases. Isis' partners are
developing drugs for a wide variety of diseases. Ibis Biosciences, Inc.,
Isis' wholly owned subsidiary, is developing and commercializing the Ibis
T5000(TM) Biosensor System, a revolutionary system to identify infectious
organisms. As an innovator in RNA-based drug discovery and development,
Isis is the owner or exclusive licens
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved